Literature DB >> 21370305

Structure analysis reveals the flexibility of the ADAMTS-5 active site.

Huey-Sheng Shieh1, Alfredo G Tomasselli, Karl J Mathis, Mark E Schnute, Scott S Woodard, Nicole Caspers, Jennifer M Williams, James R Kiefer, Grace Munie, Arthur Wittwer, Anne-Marie Malfait, Micky D Tortorella.   

Abstract

A ((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl) succinamide derivative (here referred to as Compound 12) shows significant activity toward many matrix metalloproteinases (MMPs), including MMP-2, MMP-8, MMP-9, and MMP-13. Modeling studies had predicted that this compound would not bind to ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin motifs-5) due to its shallow S1' pocket. However, inhibition analysis revealed it to be a nanomolar inhibitor of both ADAMTS-4 and -5. The observed inconsistency was explained by analysis of crystallographic structures, which showed that Compound 12 in complex with the catalytic domain of ADAMTS-5 (cataTS5) exhibits an unusual conformation in the S1' pocket of the protein. This first demonstration that cataTS5 can undergo an induced conformational change in its active site pocket by a molecule like Compound 12 should enable the design of new aggrecanase inhibitors with better potency and selectivity profiles.
Copyright © 2011 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370305      PMCID: PMC3081551          DOI: 10.1002/pro.606

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  19 in total

1.  Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue.

Authors:  R W Farndale; D J Buttle; A J Barrett
Journal:  Biochim Biophys Acta       Date:  1986-09-04

2.  Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.

Authors:  Stefan Gerhardt; Giles Hassall; Paul Hawtin; Eileen McCall; Liz Flavell; Claire Minshull; David Hargreaves; Attilla Ting; Richard A Pauptit; Andrew E Parker; W Mark Abbott
Journal:  J Mol Biol       Date:  2007-08-02       Impact factor: 5.469

3.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins.

Authors:  M D Tortorella; T C Burn; M A Pratta; I Abbaszade; J M Hollis; R Liu; S A Rosenfeld; R A Copeland; C P Decicco; R Wynn; A Rockwell; F Yang; J L Duke; K Solomon; H George; R Bruckner; H Nagase; Y Itoh; D M Ellis; H Ross; B H Wiswall; K Murphy; M C Hillman; G F Hollis; R C Newton; R L Magolda; J M Trzaskos; E C Arner
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

4.  Production of human matrix metalloproteinase 3 (stromelysin) in Escherichia coli.

Authors:  S A Rosenfeld; O H Ross; J I Corman; M A Pratta; D L Blessington; W S Feeser; B D Freimark
Journal:  Gene       Date:  1994-02-25       Impact factor: 3.688

5.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.

Authors:  Heather Stanton; Fraser M Rogerson; Charlotte J East; Suzanne B Golub; Kate E Lawlor; Clare T Meeker; Christopher B Little; Karena Last; Pamela J Farmer; Ian K Campbell; Anne M Fourie; Amanda J Fosang
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

6.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis.

Authors:  Sonya S Glasson; Roger Askew; Barbara Sheppard; Brenda Carito; Tracey Blanchet; Hak-Ling Ma; Carl R Flannery; Diane Peluso; Kim Kanki; Zhiyong Yang; Manas K Majumdar; Elisabeth A Morris
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

7.  ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms.

Authors:  Micky D Tortorella; Elizabeth C Arner; Robert Hills; Jennifer Gormley; Kam Fok; Lyle Pegg; Grace Munie; Anne-Marie Malfait
Journal:  Arch Biochem Biophys       Date:  2005-10-26       Impact factor: 4.013

8.  Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.

Authors:  I Abbaszade; R Q Liu; F Yang; S A Rosenfeld; O H Ross; J R Link; D M Ellis; M D Tortorella; M A Pratta; J M Hollis; R Wynn; J L Duke; H J George; M C Hillman; K Murphy; B H Wiswall; R A Copeland; C P Decicco; R Bruckner; H Nagase; Y Itoh; R C Newton; R L Magolda; J M Trzaskos; T C Burn
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

9.  The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation.

Authors:  M D Tortorella; A M Malfait; C Deccico; E Arner
Journal:  Osteoarthritis Cartilage       Date:  2001-08       Impact factor: 6.576

10.  Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.

Authors:  B Lovejoy; A R Welch; S Carr; C Luong; C Broka; R T Hendricks; J A Campbell; K A Walker; R Martin; H Van Wart; M F Browner
Journal:  Nat Struct Biol       Date:  1999-03
View more
  3 in total

Review 1.  Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets.

Authors:  Rachel E Miller; Yongzhi Lu; Micky D Tortorella; Anne-Marie Malfait
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

2.  Metabolic Response of Human Osteoarthritic Cartilage to Biochemically Characterized Collagen Hydrolysates.

Authors:  Saskia Schadow; Viktor S Simons; Guenter Lochnit; Jens Kordelle; Zuzana Gazova; Hans-Christian Siebert; Juergen Steinmeyer
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

3.  Molecular basis for the mechanism of action of an anti-TACE antibody.

Authors:  Li Peng; Kimberly Cook; Linda Xu; Li Cheng; Melissa Damschroder; Changshou Gao; Herren Wu; William F Dall'Acqua
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.